{"organizations": [], "uuid": "716272db5ec5c2e20aa769c863edf851a1bed0c3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-ligand-earns-6-million-as-omniab-p/brief-ligand-earns-6-million-as-omniab-partner-out-licenses-antibody-projects-idUSASB0BZLF", "country": "US", "domain_rank": 408, "title": "BRIEF-Ligand Earns $6 Million As Omniab Partner Out-Licenses Antibody Projects", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-03T16:08:00.000+02:00", "replies_count": 0, "uuid": "716272db5ec5c2e20aa769c863edf851a1bed0c3"}, "author": "", "url": "https://www.reuters.com/article/brief-ligand-earns-6-million-as-omniab-p/brief-ligand-earns-6-million-as-omniab-partner-out-licenses-antibody-projects-idUSASB0BZLF", "ord_in_thread": 0, "title": "BRIEF-Ligand Earns $6 Million As Omniab Partner Out-Licenses Antibody Projects", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "ligand pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "omniab", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "ligand", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 3, 2018 / 2:09 PM / Updated 10 minutes ago BRIEF-Ligand Earns $6 Million As Omniab Partner Out-Licenses Antibody Projects Reuters Staff \nJan 3 (Reuters) - Ligand Pharmaceuticals Inc: \n* LIGAND EARNS $6 MILLION AS OMNIAB PARTNER OUT-LICENSES ANTIBODY PROJECTS * SEES FY 2017 ADJUSTED EARNINGS PER SHARE $3.13 TO $3.16 \n* SEES FY 2017 REVENUE ABOUT $140 MILLION Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-03T16:08:00.000+02:00", "crawled": "2018-01-03T16:22:01.020+02:00", "highlightTitle": ""}